182 related articles for article (PubMed ID: 32093776)
1. Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report.
Machan S; Plaza C; Pérez-González Y; Rodriguez-Pinilla M; Requena L; Cordoba R
J Med Case Rep; 2020 Feb; 14(1):35. PubMed ID: 32093776
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
4. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
[TBL] [Abstract][Full Text] [Related]
5. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
[TBL] [Abstract][Full Text] [Related]
6. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
[TBL] [Abstract][Full Text] [Related]
7. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
Keating GM
Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
[TBL] [Abstract][Full Text] [Related]
9. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Isidori A; Loscocco F; Visani G; Paolasini S; Scalzulli P; Musto P; Perrone T; Guarini A; Pastore D; Mazza P; Tonialini L; Pavone V; De Santis G; Tarantini G
Br J Haematol; 2022 Nov; 199(3):339-343. PubMed ID: 36002151
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib-induced colitis and skin eruption mimicking graft-versus-host disease.
Hammami MB; Al-Taee A; Meeks M; Fesler M; Hurley MY; Cao D; Lai JP
Clin J Gastroenterol; 2017 Apr; 10(2):142-146. PubMed ID: 28025783
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report.
Marangon M; Pellegrini C; Argnani L; Zinzani PL
Tumori; 2017 Nov; 103(Suppl. 1):e41-e43. PubMed ID: 28967090
[TBL] [Abstract][Full Text] [Related]
12. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
Flinn IW; Kahl BS; Leonard JP; Furman RR; Brown JR; Byrd JC; Wagner-Johnston ND; Coutre SE; Benson DM; Peterman S; Cho Y; Webb HK; Johnson DM; Yu AS; Ulrich RG; Godfrey WR; Miller LL; Spurgeon SE
Blood; 2014 May; 123(22):3406-13. PubMed ID: 24615776
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Analysis of the Impact of Adverse Event-Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients With Relapsed/Refractory B-Cell Malignancies.
Ma S; Chan RJ; Gu L; Xing G; Rajakumaraswamy N; Ruzicka BB; Wagner-Johnston ND
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):e432-e448. PubMed ID: 33516721
[TBL] [Abstract][Full Text] [Related]
15. Acute polyradiculopathy secondary to idelalisib in Relapsed Classical Hodgkin's lymphoma.
Barbieux S; Boyle EM; Baillet C; Demarquette H; Vermersch P; Morschhauser F; Herbaux C
Curr Res Transl Med; 2018 Sep; 66(3):87-89. PubMed ID: 30191811
[TBL] [Abstract][Full Text] [Related]
16. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
17. Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma.
Hengeveld PJ; de Jongh E; Westerweel PE; Levin MD
BMJ Case Rep; 2020 Jul; 13(7):. PubMed ID: 32624488
[TBL] [Abstract][Full Text] [Related]
18. Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.
Okoli TC; Peer CJ; Dunleavy K; Figg WD
Cancer Biol Ther; 2015; 16(2):204-6. PubMed ID: 25756507
[TBL] [Abstract][Full Text] [Related]
19. Idelalisib approved for three blood cancers.
Traynor K
Am J Health Syst Pharm; 2014 Sep; 71(17):1430. PubMed ID: 25147161
[No Abstract] [Full Text] [Related]
20. Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.
Louie CY; DiMaio MA; Matsukuma KE; Coutre SE; Berry GJ; Longacre TA
Am J Surg Pathol; 2015 Dec; 39(12):1653-60. PubMed ID: 26426383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
